Are we there yet?
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
The trigger for a Seagen buyout
Seagen is vulnerable to takeover, but whether a deal happens – and at what price – depends on at least one catalyst.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
To buy or build blockbusters?
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Looking beyond Roche’s Tigit bombshell
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
